LETTER TO THE EDITOR: Interferon is not an optimal treatment for chronic hepatitis delta but needs 'fair treatment' by us.

Kamal et al. assessed the impact of hepatitis D virus (HDV) viremia on liver related outcomes (1). The study reveals the real world situation of the management of chronic hepatitis D (CHD) in a country where the disease is rare. Active viral replication was associated with liver related events in CHD. In their study, 108 patients received interferon (IFN) therapy, and 19 became HDV RNA negative at 24/48 week after IFN treatment. Viral response was not associated with lower risk of liver related events.